The neoadjuvant combination of pembrolizumab with the TLR9 agonist vidutolimod generated higher pCR rates vs pembrolizumab alone, as well as an acceptable safety profile, in patients with macroscopic, resectable stage III #Melanoma. Ahmad Tarhini @MoffitNews

In an interview with Ahmad Tarhini, he discussed: 👉 The rationale for combining a PD-1 inhibitor with a TLR9 agonist 👉 Key efficacy and safety findings from the EA6194 trial 👉 How these data support the continued investigation of vidutolimod in patients with #Melanoma

Ahmad Tarhini Read the Q&A: onclive.com/view/neoadjuva… Moffitt Cancer Center

Published by VJ Oncology | My interview at #ASCO25 #MoffittASCO25 #Chicago ECOG-ACRIN Cancer Research Group National Cancer Institute Moffitt Cancer Center Moffitt Research vjoncology.com/video/aev8wkmw…

New in OncLive.com | ECOG-ACRIN Cancer Research Group's #EA6194 study | Neoadjuvant Vidutolimod + Pembrolizumab Displays High pCR Rates in Resectable #Melanoma | data presented at ASCO #ASCO25 by Ahmad Tarhini | supported by ⁦National Cancer Institute ⁩ onclive.com/view/neoadjuva… via @onclive

Honored to give the Hematology Oncology Grand Rounds ⁦Corewell Health⁩ ⁦Beaumont Health⁩ in #Michigan this AM discussing #Melanoma #Immunotherapy #Immunooncology & #Molecularlytargetedtherapy | Grateful to Dr. Ishmael Jaiyesimi & colleagues ⁦⁦Moffitt Cancer Center⁩

Looking forward to the exciting ⁦⁦Oncology Learning Network⁩ live debates | Great Debates in Solid Tumors conference | Pleasure to join Drs ⁦Jose Lutzky, MD, FACP &⁩ ⁦⁦Jim Smithy⁩ Sep13 #Miami ⁦Moffitt Cancer Center⁩ ⁦Sylvester Comprehensive Cancer Center⁩ ⁦⁦⁦Memorial Sloan Kettering Cancer Center⁩

Published by ⁦Oncology News Central⁩ | I had a great conversation with Dr ⁦Jim Smithy⁩ & Dr Michael Postow on the latest in #Melanoma #Immunotherapy & #MolecularlyTargetedTherapy - Navigating Options ⁦Moffitt Cancer Center⁩ ⁦Memorial Sloan Kettering Cancer Center⁩ oncologynewscentral.com/video/melanoma…

#FindingsFriday: Exciting results from EA6194, a #ClinicalTrial for stage 3 resectable #melanoma, were recently highlighted by @onclive. Presented at #ASCO25 by Ahmad Tarhini, these findings show promise for a new treatment combination. Read more: bit.ly/47TEQx6

Global Health Catalyst Summit at #Harvard & #MIT | Excited to share our vision & efforts ⁦⁦Society for Immunotherapy of Cancer⁩ toward advancing #cancer #immunotherapy | Honored to join Jennifer Dent ⁩& ⁦Dr. Catharine Young⁩ Sep 21 ⁦⁦⁦⁦Moffitt Cancer Center⁩ globalhealthcatalystsummit.org/program

Our latest published article in Nature Medicine |#Neoadjuvant #PD1 & #LAG3 #BispecificAntibody & other #ImmuneCheckpointInhibitor combinations in #Melanoma | Great international collaborative effort with an outstanding group of investigators Moffitt Cancer Center nature.com/articles/s4159…

🎥Ahmad Tarhini from Moffitt Cancer Center reports EA6194: neoadjuvant pembrolizumab + vidutolimod improved pathologic responses vs pembro alone in resectable melanoma, w/ manageable safety: ➡️ ow.ly/916T50X36qT⬅️ ASCO #ASCO25 #Melsm #Skcsm #ImmunoOnc #CTSM #TrialUpdate This

#Melanoma & #Skincancer Mole Patrole at #TempleTerrace #FireDepartment Open House #FireResponders #EMS ⁦Temple Terrace, FL⁩ with an amazing ⁦Moffitt Cancer Center⁩ volunteer team │ Here #forthecure & #cancer #awareness #education & #prevention

#ESMO25 Abstracts Released | Among ours: Systematic Evaluation of #PolygenicRiskScores for #Autoimmune #Thyroid Disease & Risk of #Thyroiditis Following #ImmuneCheckpoint #Immunotherapy of #Melanoma | Presenting in #Berlin ⁦ECOG-ACRIN Cancer Research Group⁩ ⁦National Cancer Institute⁩ ⁦⁦Moffitt Cancer Center⁩

Tune in at #ESMO25 as Ahmad Tarhini, MD, PhD (Ahmad Tarhini) shares how polygenic risk scores (PRS) may help predict thyroiditis risk in melanoma patients receiving checkpoint immunotherapy. Findings could help personalize follow-up and improve patient care.

Our latest published article in ⁦Nature Medicine⁩ |#Adjuvant #nivolumab & #relatlimab in #melanoma: The phase 3 RELATIVITY-098 trial | Honored to serve on the scientific steering committee with this outstanding group ⁦⁦⁦⁦Moffitt Cancer Center⁩ nature.com/articles/s4159…

At #ESMO25, Ahmad Tarhini, MD, PhD (Ahmad Tarhini), presents his poster evaluating polygenic risk scores (PRS) for autoimmune thyroid disease and their association with thyroiditis following checkpoint immunotherapy for melanoma. Findings suggest PRS may help predict

#London #UK #ESMOImmuno25 | Honored to serve as Organizer with ⁦Thommen Lab⁩ for the #SITC Primer - #Neoadjuvant #Immunotherapy #SpatialBiology Novel #Immunomodulators #Multiomics & #AI | Great speakers & science ⁦ESMO - Eur. Oncology⁩ ⁦Society for Immunotherapy of Cancer⁩ ⁦⁦Moffitt Cancer Center⁩

Our latest presented by ⁦Peter Kanetsky⁩ at Society for Melanoma Research Congress #SMR2025 in #Amsterdam | #Exercise to boost response to #ImmuneCheckpointInhibitors in #SkinCancer | #Exercise feasible & promising in #ImmunoOncology #CancerResearch ⁦Moffitt Cancer Center⁩ ⁦

#SITC25 Abstracts Released | Among ours: A Novel #PolygenicRiskScore Predicts #ImmuneCheckpoint Inhibitor Mediated #Dermatitis in a North American #Melanoma Patient Population | #ImmunoOncology #irAEs ⁦Society for Immunotherapy of Cancer⁩ ECOG-ACRIN Cancer Research Group National Cancer Institute Moffitt Cancer Center sitcancer.org/2025/abstracts…